ΓΙΑ ΝΑ ΕΜΒΟΛΙΑΣΘΕΊΤΕ ΚΑΤΆ ΤΟΥ COVID - 19 KATA ΣΕΙΡΑ ΠΡΟΤΕΡΑΙΌΤΗΤΑΣ ΚΑΙ ΝΑ ΜΆΘΕΤΕ ΤΙ ΔΙΚΑΙΟΛΟΓΗΤΙΚΑ ΠΡΈΠΕΙ ΝΑ ΠΡΟΣΚΟΜΊΣΕΤΕ ΣΤΑ ΝΟΣΟΚΟΜΕΊΑ ΠΡΟΣ ΤΟ ΠΑΡΟΝ ΌΠΟΥ ΘΑ ΕΜΒΟΛΙΑΣΘΕΊΤΕ ΠΑΤΉΣΤΕ ΣΤΟΝ ΣΎΝΔΕΣΜΟ :
Τετάρτη 13 Ιανουαρίου 2021
Τρίτη 29 Δεκεμβρίου 2020
General Considerations
General Considerations
In late 2019, a novel coronavirus emerged, spreading quickly from its origin in China across the globe. The CDCrecommended terminology for the virus is SARS-CoV-2, and the illness caused by this virus is called “Coronavirus Disease 2019” or COVID-19 (https://www.cdc.gov/coronavirus/2019-ncov/summary.html). COVID-19 was declared a pandemic by the WHO on March 11, 2020. The earliest known case in the United States was documented on January 21, 2020, in a man who had recently returned to the state of Washington from China. The first US case that was not associated with travel or contact with infected travelers was identified in February 2020 in Solano, California. As of May 22, 2020, the confirmed number of global cases is over 5.1 million, including more than 333,000 deaths.
ΠΕΡΙΣΣΟΤΕΡΑ ΓΙΑ ΤΟΝ COVID - 19 . (3 ΑΡΧΕΙΑ)
Severe Acute Respiratory Syndrome—Coronavirus 2019 (SARS-CoV-2)
Severe Acute Respiratory Syndrome—Coronavirus 2019 (SARS-CoV-2)
ESSENTIALS OF DIAGNOSIS
Wide spectrum of symptoms.
Asymptomatic in at least 20–35%.
Upper respiratory tract illness with fever and cough most often when symptomatic.
The clinical triad of cough, fever, and dyspnea is infrequent (less than 15%).
Advanced pulmonary complications (pneumonia, acute respiratory distress syndrome [ARDS]) with fulminant
disease.
Mortality of 1–21% (the higher for the New York City outbreak).
High predilection for the elderly, the immunocompromised, those with chronic diseases, those living in crowded
conditions.
MEDICAL SOURCES 29/12/2020
Κυριακή 27 Δεκεμβρίου 2020
When to Admit for corona virus infection covid-19
When to Admit for coronavirus covid - 19 infection
The principal complications requiring admission are respiratory. Progression to respiratory failure and ARDS can be rapid, and any patient in a high-risk category for complications (advanced age; immunosuppression; chronic diseases, particularly hypertension, obesity, and diabetes) should be admitted for observation and placed under intensive care based on respiratory parameters. Corey BL et al. A strategic approach to COVID-19 vaccine R&D. Science. 2020 May 11. [Epub ahead of print] [PMID: 32393526] JAMA Coronavirus Disease 2019 (COVID 19). https://jamanetwork.com/journals/jama/pages/coronavirus-alert Lancet COVID-19 Resource Centre. https://www.thelancet.com/coronavirus?dgcid=kr_pop-up_tlcoronavirus20
Moore BJB et al. Cytokine release syndrome in severe COVID-19. Science. 2020 May 1;368(6490):473–4. [PMID: 32303591] New England Journal of Medicine-coronavirus (COVID-19). https://www.nejm.org/coronavirus Riphagen S et al. Hyperinflammatory shock in children during COVID-19 outbreak. The Lancet Online. 2020 May 6. Published online. https://doi.org/10.1016/S0140-6736(20)31094-1. Wang Y et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020;395(10236):1569–78. [PMID: 32423584]
medical sources 27/12/2020
Σάββατο 26 Δεκεμβρίου 2020
Παρασκευή 18 Δεκεμβρίου 2020
Japan’s Hayabusa 2 mission returns asteroid sample to Earth
Japan’s Hayabusa 2 mission returns asteroid sample to Earth
08 Dec 2020 Michael Banks
The Japanese space agency, JAXA, has successfully retrieved a 16 kg capsule that is hoped to contain flecks of an asteroid. The capsule landed in Australia’s remote outback following a six-year mission by the $250m Hayabusa 2 mission to retrieve samples from the asteroid Ryugu. Scientists will now study the contents of the capsule to find out about the origin of the asteroid’s organic matter and water and how these are related to life and ocean water on Earth.
Εγγραφή σε:
Αναρτήσεις (Atom)